Mardge H Cohen1, Anna L Hotton, Ronald C Hershow, Alexandra Levine, Peter Bacchetti, Elizabeth T Golub, Kathryn Anastos, Mary Young, Deborah Gustafson, Kathleen M Weber. 1. *Department of Medicine, Stroger Hospital and Rush Medical Center, Chicago, IL; †The CORE Center, Cook County Health and Hospital System, Chicago, IL; ‡Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, IL; §City of Hope, Los Angeles, CA; ‖Division of Biostatistics, School of Medicine, University of California, San Francisco, CA; ¶Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; #Department of Neurology of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY; **Division of Infectious Diseases, Georgetown University, Washington, DC; and ††Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY.
Abstract
BACKGROUND: Adding gender-related modifiable characteristics or behaviors to the Veterans Aging Cohort Study (VACS) index might improve the accuracy of predicting mortality among HIV-infected women on treatment. We evaluated the VACS index in women with HIV, determined whether additional variables would improve mortality prediction, and quantified the potential for improved survival associated with reduction in these additional risk factors. METHODS: The VACS index (based on age, CD4 count, HIV-1 RNA, hemoglobin, aspartate aminotransferase, alanine aminotransferase, platelets, creatinine, and Hepatitis C status) was validated in HIV-infected women in the Women's Interagency HIV Study (WIHS) who initiated antiretroviral therapy between January 1996 and December 2007. Models were constructed adding race, depression, abuse, smoking, substance use, transactional sex, and comorbidities to determine whether predictability improved. Population attributable fractions were calculated. RESULTS: The VACS index accurately predicted 5-year mortality in 1057 WIHS women with 1 year on highly active antiretroviral therapy with c-index 0.83 [95% confidence interval (CI): 0.79 to 0.87]. In multivariate analysis, the VACS index score [adjusted hazard ratio (aHR) for a 5-point increment 1.30; 95% CI: 1.25 to 1.35], depressive symptoms (aHR 1.73; 95% CI: 1.17 to 2.56), and history of transactional sex (aHR 1.93; 95% CI: 1.33 to 1.82) were independent statistically significant predictors of mortality. CONCLUSIONS: Both depression and transactional sex significantly improved the performance of the VACS index in predicting mortality among HIV-infected women. Providing treatment for depression and addressing economic and psychosocial instability in HIV-infected women would improve health and perhaps point to a broader public health approach to reducing HIV mortality.
BACKGROUND: Adding gender-related modifiable characteristics or behaviors to the Veterans Aging Cohort Study (VACS) index might improve the accuracy of predicting mortality among HIV-infectedwomen on treatment. We evaluated the VACS index in women with HIV, determined whether additional variables would improve mortality prediction, and quantified the potential for improved survival associated with reduction in these additional risk factors. METHODS: The VACS index (based on age, CD4 count, HIV-1 RNA, hemoglobin, aspartate aminotransferase, alanine aminotransferase, platelets, creatinine, and Hepatitis C status) was validated in HIV-infectedwomen in the Women's Interagency HIV Study (WIHS) who initiated antiretroviral therapy between January 1996 and December 2007. Models were constructed adding race, depression, abuse, smoking, substance use, transactional sex, and comorbidities to determine whether predictability improved. Population attributable fractions were calculated. RESULTS: The VACS index accurately predicted 5-year mortality in 1057 WIHS women with 1 year on highly active antiretroviral therapy with c-index 0.83 [95% confidence interval (CI): 0.79 to 0.87]. In multivariate analysis, the VACS index score [adjusted hazard ratio (aHR) for a 5-point increment 1.30; 95% CI: 1.25 to 1.35], depressive symptoms (aHR 1.73; 95% CI: 1.17 to 2.56), and history of transactional sex (aHR 1.93; 95% CI: 1.33 to 1.82) were independent statistically significant predictors of mortality. CONCLUSIONS: Both depression and transactional sex significantly improved the performance of the VACS index in predicting mortality among HIV-infectedwomen. Providing treatment for depression and addressing economic and psychosocial instability in HIV-infectedwomen would improve health and perhaps point to a broader public health approach to reducing HIV mortality.
Authors: Judith A Cook; Jane K Burke-Miller; Mardge H Cohen; Robert L Cook; David Vlahov; Tracey E Wilson; Elizabeth T Golub; Rebecca M Schwartz; Andrea A Howard; Claudia Ponath; Michael W Plankey; Alexandra M Levine; Andrea Levine; Dennis D Grey Journal: AIDS Date: 2008-07-11 Impact factor: 4.177
Authors: Mardge H Cohen; Judith A Cook; Dennis Grey; Mary Young; Lawrence H Hanau; Phyllis Tien; Alexandra M Levine; Tracey E Wilson Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: Judith A Cook; Dennis Grey; Jane Burke; Mardge H Cohen; Alejandra C Gurtman; Jean L Richardson; Tracey E Wilson; Mary A Young; Nancy A Hessol Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: Jane Leserman; Brian Wells Pence; Kathryn Whetten; Michael J Mugavero; Nathan M Thielman; Marvin S Swartz; Dalene Stangl Journal: Am J Psychiatry Date: 2007-11 Impact factor: 18.112
Authors: Amy C Justice; Sharada P Modur; Janet P Tate; Keri N Althoff; Lisa P Jacobson; Kelly A Gebo; Mari M Kitahata; Michael A Horberg; John T Brooks; Kate Buchacz; Sean B Rourke; Anita Rachlis; Sonia Napravnik; Joseph Eron; James H Willig; Richard Moore; Gregory D Kirk; Ronald Bosch; Benigno Rodriguez; Robert S Hogg; Jennifer Thorne; James J Goedert; Marina Klein; John Gill; Steven Deeks; Timothy R Sterling; Kathryn Anastos; Stephen J Gange Journal: J Acquir Immune Defic Syndr Date: 2013-02-01 Impact factor: 3.731
Authors: Lorenzo Cohen; Steven W Cole; Anil K Sood; Sarah Prinsloo; Clemens Kirschbaum; Jesusa M G Arevalo; Nicholas B Jennings; Shellie Scott; Luis Vence; Qi Wei; Diane Kentor; Laszlo Radvanyi; Nizar Tannir; Eric Jonasch; Pheroze Tamboli; Louis Pisters Journal: PLoS One Date: 2012-08-01 Impact factor: 3.240
Authors: Anna L Hotton; Kathleen M Weber; Ronald C Hershow; Kathryn Anastos; Peter Bacchetti; Elizabeth T Golub; Deborah Gustafson; Alexandra M Levine; Mary Young; Mardge H Cohen Journal: J Acquir Immune Defic Syndr Date: 2017-06-01 Impact factor: 3.731
Authors: Amanda M Kong; Alexis Pozen; Kathryn Anastos; Elizabeth A Kelvin; Denis Nash Journal: AIDS Patient Care STDS Date: 2019-03 Impact factor: 5.078
Authors: Brian W Pence; Jon C Mills; Angela M Bengtson; Bradley N Gaynes; Tiffany L Breger; Robert L Cook; Richard D Moore; David J Grelotti; Conall O'Cleirigh; Michael J Mugavero Journal: JAMA Psychiatry Date: 2018-04-01 Impact factor: 21.596
Authors: Michele R Decker; Lorie Benning; Kathleen M Weber; Susan G Sherman; Adebola Adedimeji; Tracey E Wilson; Jennifer Cohen; Michael W Plankey; Mardge H Cohen; Elizabeth T Golub Journal: Am J Prev Med Date: 2016-08-29 Impact factor: 5.043
Authors: Mardge H Cohen; Kathleen M Weber; Nicola Lancki; Stephen J Gange; Michael Plankey; Morgan M Philbin; Joel Milam; Adaora A Admora; Mirjam-Colette Kempf; Susan Holman; Jennifer Cohen; Antonina Foster; Oluwakemi Sosanya; Charlesnika T Evans Journal: J Womens Health (Larchmt) Date: 2019-05-17 Impact factor: 2.681
Authors: Jon C Mills; Brian W Pence; Jonathan V Todd; Angela M Bengtson; Tiffany L Breger; Andrew Edmonds; Robert L Cook; Adebola Adedimeji; Rebecca M Schwartz; Seble Kassaye; Joel Milam; Jennifer Cocohoba; Mardge Cohen; Elizabeth Golub; Gretchen Neigh; Margaret Fischl; Mirjam-Colette Kempf; Adaora A Adimora Journal: Clin Infect Dis Date: 2018-10-30 Impact factor: 9.079
Authors: Yuhang Qian; Richard D Moore; Sally B Coburn; Thibaut Davy-Mendez; Kathleen M Akgün; Kathleen A McGinnis; Michael J Silverberg; Jonathan A Colasanti; Edward R Cachay; Michael A Horberg; Charles S Rabkin; Jeffrey M Jacobson; M John Gill; Angel M Mayor; Gregory D Kirk; Kelly A Gebo; Ank E Nijhawan; Keri N Althoff Journal: J Acquir Immune Defic Syndr Date: 2022-01-01 Impact factor: 3.771